{"id":"ibandronate-sb743830hd","safety":{"commonSideEffects":[{"rate":null,"effect":"Musculoskeletal pain"},{"rate":null,"effect":"Gastrointestinal upset (nausea, dyspepsia)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Osteonecrosis of the jaw (rare, with prolonged use)"},{"rate":null,"effect":"Atypical fractures (rare)"}]},"_chembl":{"chemblId":"CHEMBL3989569","moleculeType":"Small molecule","molecularWeight":"359.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bisphosphonates like ibandronate are taken up by osteoclasts during bone resorption and inhibit the mevalonate pathway enzyme farnesyl pyrophosphate synthase, leading to osteoclast apoptosis and reduced bone turnover. This mechanism decreases bone resorption and increases bone mineral density, making it effective for conditions characterized by excessive bone loss.","oneSentence":"Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:49.552Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Bone metastases in breast cancer"},{"name":"Hypercalcemia of malignancy"}]},"trialDetails":[{"nctId":"NCT00405392","phase":"PHASE4","title":"Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-22","conditions":"Osteoporosis, Postmenopausal","enrollment":365}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ibandronate (SB743830HD)","genericName":"Ibandronate (SB743830HD)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Osteoporosis in postmenopausal women, Bone metastases in breast cancer, Hypercalcemia of malignancy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}